Akari's robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses …
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
NEW YORK and LONDON, September 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
NEW YORK and LONDON, September 12, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Announces $12.75 Million Registered Direct Offering
Thrombotic Microangiopathy
Thrombotic microangiopathy following a stem cell transplant is a rare but serious complication that often leads to progressive organ damage and death. Akari is …
